0
0
New Delhi – In a significant statement addressing concerns over the availability of life-saving medications, Union Minister of State for Health Anupriya Patel assured the Rajya Sabha on Tuesday that there is “no scarcity” of essential anti-tuberculosis drugs in India’s central and state warehouses.
The assurance comes at a critical juncture for India’s National Tuberculosis Elimination Programme (NTEP), which has set an ambitious target to eliminate the disease by 2025, five years ahead of the global Sustainable Development Goal.
Government Stance: Robust Stocks and Supply Chain Reforms
Responding to a query regarding reported shortages and delays in tender finalizations, Minister Patel categorically stated that stocks of first-line drugs, specifically Rifampicin and Ethambutol, remain sufficient.
“There are no shortages of any key anti-TB drugs… in the Central and State warehouses,” Patel affirmed in her written reply. She outlined several strategic measures the Ministry has implemented to prevent future disruptions:
-
Rate Contract Model (2025-27): A long-term procurement strategy has been established for all drugs, including newer, shorter-regimen treatments, to ensure price stability and supply continuity.
-
Real-Time Monitoring: The government is leveraging the Drugs and Vaccines Distribution Management System (DVDMS) to track drug availability and utilization in real-time, allowing for rapid redistribution if local stockouts occur.
-
Enhanced Supervision: Regular physical stock verification by state and national teams is being conducted to bridge the gap between digital data and ground reality.
The Data Landscape: Progress Mixed with Persistent Burden
The Minister’s statement was underscored by data from the newly released World Health Organization (WHO) Global TB Report 2025. The report paints a picture of substantial progress but highlights the immense scale of the challenge remaining.
In 2024, India recorded an estimated 21.7 lakh (2.17 million) tuberculosis cases and approximately 3 lakh deaths due to the infection. While these numbers are stark, they represent a significant downward trend. India has achieved a 21% decline in TB incidence between 2015 and 2024, a rate nearly double the global average decline. Furthermore, treatment coverage has surged to 92% in 2024, up from just 53% in 2015, indicating that more patients are being diagnosed and brought under the ambit of care.
Ground Reality: Contextualizing the “Shortage” Narrative
While the government’s assurance covers key first-line drugs, health activists and independent experts have pointed to intermittent disruptions, particularly affecting second-line drugs used for Multi-Drug Resistant TB (MDR-TB).
Over the past year, civil society groups, including Survivors Against TB and Jan Swasthya Andolan, have raised alarms regarding sporadic stockouts of critical MDR-TB medications such as Linezolid, Cycloserine, and Moxifloxacin in various states.
“Stockouts of TB drugs are often not because of inadequate funds allocated but because tenders are not processed in time,” noted Leena Meghnaney, a global health policy expert, in earlier commentary regarding supply chain bottlenecks.
The distinction is crucial: while first-line drugs (for drug-sensitive TB) may be stable, the supply chain for second-line treatments—vital for patients who do not respond to standard therapy—remains a complex challenge. Any interruption in these regimens is particularly dangerous, as it can lead to further drug resistance, making the disease even harder and more expensive to treat.
Expert Perspectives: The Cost of Interruption
Ganesh Acharya, a prominent TB survivor and activist based in Mumbai, has repeatedly emphasized the human cost of these logistical gaps. “We acknowledge the considerable progress made… However, frequent stockouts of anti-TB drugs threaten to undo these gains,” Acharya has stated in correspondence to the Health Ministry. “Inadequate and poorly administered treatment regimens facilitate drug resistance.”
For patients, the implications of stockouts are severe. A break in medication not only leads to a relapse of symptoms but can turn a treatable infection into a drug-resistant strain, significantly lowering survival rates.
Implications for Public Health
The government’s proactive shift to a “Rate Contract Model” for 2025-27 is a direct response to these valid concerns. By securing prices and suppliers for a two-year window, the Ministry aims to bypass the bureaucratic delays that have historically plagued annual tender processes.
For the general public and healthcare professionals, the takeaway is twofold:
-
Adherence is Non-Negotiable: With the government assuring stock availability, patients must be encouraged to adhere strictly to their regimens.
-
Vigilance is Required: Localized shortages may still occur due to distribution lags. Patients are advised to utilize the grievance redressal mechanisms available under the NTEP if they encounter denial of service.
Conclusion
India’s battle against tuberculosis is entering its final, most difficult phase. While the Minister’s assurance of “no scarcity” provides a necessary confidence boost in the public health system, the concerns raised by civil society serve as an essential check. Ensuring that the “adequate buffer” exists not just in central warehouses but at the last mile—in the hands of the patient—will be the true test of India’s readiness to eliminate TB.
Medical Disclaimer:
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
-
Primary Source: Press Trust of India (PTI). (2025, December 10). “No scarcity of key anti-TB drugs in central, state stocks: Union minister.” The Economic Times Healthworld.
